skip to main content

hs-CRP and Inflammatory Hypothesis — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGeneral Cardiologyhs-CRP and Inflammatory HypothesisEECC

A 65-year-old man with heart failure is found to have an elevated high-sensitivity C-reactive protein (hs-CRP) of 8.5 mg/L with no obvious infection. What is the clinical significance of elevated hs-CRP in the context of cardiovascular risk?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — hs-CRP is a marker of systemic inflammation that independently predicts cardiovascular events; the CANTOS trial demonstrated that anti-inflammatory therapy with canakinumab (anti-IL-1β antibody) reduced MACE in patients with elevated hs-CRP, providing proof-of-concept for the inflammatory hypothesis of atherosclerosis

hs-CRP is a downstream marker of systemic inflammation that independently predicts cardiovascular events even after adjustment for traditional risk factors. Risk categories: <1 mg/L = low, 1-3 mg/L = moderate, >3 mg/L = high cardiovascular risk. The CANTOS trial (canakinumab, anti-IL-1β) provided landmark proof that targeting inflammation (reducing hs-CRP) reduces cardiovascular events independent of lipid lowering. The subsequent COLCOT and LoDoCo2 trials (colchicine — a more practical anti-inflammatory) further supported the inflammatory hypothesis. The ESC Prevention Guidelines include hs-CRP as a risk modifier and acknowledge the therapeutic potential of anti-inflammatory approaches, though routine anti-inflammatory therapy for CV prevention is not yet standard.

Reference: ESC (2021): CVD Prevention Guidelines; CANTOS Trial